Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer.
Author(s)
Type
Journal Article
Abstract
In this report from the CAPTURE study (NCT03226886), we demonstrate that a third dose of COVID-19 vaccine boosts neutralizing antibody (NAb) and cellular responses in patients with cancer, including those that had undetectable NAb titers (NAbT) following two vaccine doses or for whom NAbT waned. We have noted that one key member of the CAPTURE consortium—Sanjay Popat—was inadvertently not included in the author list. We now include him as a co-author. There are no additional changes to the declaration of interests statement, since Dr. Popat declares no competing conflict of interest. This author list change is now reflected in the online version of this letter.
Date Issued
2022-04-11
Date Acceptance
2022-02-01
Citation
Cancer Cell, 2022, 40 (4), pp.438-438
ISSN
1535-6108
Publisher
Cell Press
Start Page
438
End Page
438
Journal / Book Title
Cancer Cell
Volume
40
Issue
4
Copyright Statement
© 2022 Elsevier Inc
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/35413273
PII: S1535-6108(22)00125-8
Subjects
Crick COVID19 consortium
CAPTURE consortium
1109 Neurosciences
1112 Oncology and Carcinogenesis
Oncology & Carcinogenesis
Publication Status
Published
Coverage Spatial
United States